LifeStance Health Group (NASDAQ:LFST) Stock Rating Upgraded by Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other brokerages also recently weighed in on LFST. UBS Group upped their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. BTIG Research boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Barclays started coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price for the company. Finally, BMO Capital Markets began coverage on shares of LifeStance Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, LifeStance Health Group presently has an average rating of “Moderate Buy” and an average price target of $8.83.

LifeStance Health Group Stock Performance

LFST opened at $7.34 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.86 billion, a PE ratio of -244.67 and a beta of 1.12. The business has a fifty day simple moving average of $6.88 and a 200-day simple moving average of $5.72. LifeStance Health Group has a fifty-two week low of $3.74 and a fifty-two week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The business had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) earnings per share. As a group, equities analysts predict that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In related news, insider Ann Varanakis sold 50,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the transaction, the insider directly owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 327,326 shares of company stock worth $2,259,317 over the last three months. Corporate insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its position in LifeStance Health Group by 259.1% in the second quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock worth $7,031,000 after purchasing an additional 981,349 shares during the period. OLD National Bancorp IN acquired a new position in shares of LifeStance Health Group in the 3rd quarter valued at $508,000. AXQ Capital LP bought a new position in shares of LifeStance Health Group during the 2nd quarter worth about $343,000. TD Asset Management Inc acquired a new stake in shares of LifeStance Health Group during the 2nd quarter valued at about $780,000. Finally, Loomis Sayles & Co. L P increased its stake in LifeStance Health Group by 4.5% in the second quarter. Loomis Sayles & Co. L P now owns 2,343,028 shares of the company’s stock valued at $12,113,000 after acquiring an additional 100,657 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.